Related Experiment Videos
[Transdermal therapy of erectile insufficiency]
D Canale1, P Cilurzo, P M Giorgi
1Scuola di Specializzazione in Andrologia e Centro di Andrologia, Università degli Studi di Pisa.
Archivio Italiano Di Urologia, Nefrologia, Andrologia : Organo Ufficiale Dell'Associazione Per La Ricerca in Urologia = Urological, Nephrological, and Andrological Sciences
|September 1, 1992
Summary
Transdermal drug delivery offers a safer alternative to intracavernosal injections for treating impotence. Yohimbine ointment and a controlled transdermal system showed promising results, particularly for mild cases.
Area of Science:
- Urology
- Pharmacology
- Andrology
Background:
- Intracavernosal injections for erectile dysfunction (ED) carry risks like fibrosis and priapism.
- Transdermal drug administration presents a potential alternative to invasive methods.
- Evaluating novel delivery systems for ED treatment is crucial.
Purpose of the Study:
- To investigate the efficacy and safety of transdermal (TS) drug administration for impotence.
- To assess yohimbine (YOH) effectiveness as a transdermal ointment.
- To evaluate a controlled transdermal drug administration system (CTDAS) with papaverine.
Main Methods:
- A double-blind crossover trial involving 62 patients treated with yohimbine ointment applied to the balanopreputial sulcus.
- High-performance liquid chromatography (HPLC) was used to measure yohimbine levels in corpora cavernosa blood.
- A controlled transdermal drug administration system (CTDAS) was employed for papaverine delivery.
Main Results:
- Transdermal yohimbine demonstrated rapid absorption, with peak blood levels of 58 ng/ml at 25 minutes in 10 patients.
- Yohimbine treatment was most effective in patients with recent-onset, mild impotence without significant vascular issues.
- The CTDAS system showed that approximately 10% of patients experienced relevant improvements in erectile function.
Conclusions:
- Transdermal drug administration is a viable and potentially safer alternative for impotence treatment.
- Yohimbine and papaverine delivered transdermally show promise, especially for specific patient subgroups.
- Further research into transdermal systems could optimize ED management.